Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

10.19 +0.19 (+1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
Via InvestorPlace
News headline image
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
From Pomerantz LLP
Via GlobeNewswire
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
On Tuesday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
Topics Artificial Intelligence
News headline image
Which stocks are moving on Monday? ↗
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
What's going on in today's session ↗
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at Two Upcoming Investor Conferences
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Replimune, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure 
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
News headline image
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
The Best AI for Picking Stocks, Ranked by Performance ↗
AI can pick stocks, but that doesn't mean it will do a good job. Here's a look at how the choices made by 7 leading AIs performed over a 90-day time period. 
Via MarketBeat
Topics Artificial Intelligence ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.